Cost-effectiveness of combination therapy with etravirine in treatment-experienced adults with HIV-1 infection

AIDS

Volumn 26, Issue 3, 2012, Pages 355-364

  Mauskopf, Josephine ^a   Brogan, Anita J ^a   Talbird, Sandra E ^a   Martin, Silas ^b  

^a RTI HEALTH SOLUTIONS   (United States)

^b Janssen Services LLC   (United States)

Author keywords

antiretroviral therapy; cost effectiveness; costs; economic model; HIV; reverse transcriptase inhibitors

Indexed keywords

DARUNAVIR PLUS RITONAVIR; ETRAVIRINE;

AGED; ANTIVIRAL THERAPY; ARTICLE; CANADA; CD4 LYMPHOCYTE COUNT; CLINICAL TRIAL (TOPIC); CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; DRUG COST; FEMALE; HOSPITALIZATION; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIORITY JOURNAL; PROBABILITY; QUALITY ADJUSTED LIFE YEAR; SENSITIVITY ANALYSIS; VALIDATION PROCESS; VIRUS LOAD;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ADOLESCENT; ADULT; AGED; ANTI-HIV AGENTS; CANADA; CD4 LYMPHOCYTE COUNT; COST-BENEFIT ANALYSIS; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; HIV-1; HUMANS; MALE; MARKOV CHAINS; MIDDLE AGED; MODELS, ECONOMIC; PYRIDAZINES; QUALITY-ADJUSTED LIFE YEARS; RITONAVIR; SULFONAMIDES; VIRAL LOAD; YOUNG ADULT;

EID: 84855351867     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0b013e32834e87e6     Document Type: Article

References (40)

1. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. US Department of Health and Human Services. (2011). http://aidsinfo.nih.gov/ contentfiles/Adultand AdolescentGL.pdf. [Accessed 31 March 2011].
2. Bartlett JA, Buda JJ, von Scheele B, Mauskopf JA, Davis EA, Elston R, et al. Minimizing resistance consequences after virologic failure on initial combination therapy: a systematic overview. J Acquir Immune Defic Syndr 2006; 41:323-331.
3. Katlama C, Haubrich R, Lalezari J, Lazzarin A, Madruga JV, Molina JM, et al. Efficacy and safety of etravirine in treatmentexperienced, HIV-1 patients: pooled 48 week analysis of two randomized, controlled trials. AIDS 2009; 23:2289-2300.
4. Katlama C, Clotet B, Mills A, Trottier B, Molina JM, Grinsztejn B, et al. Efficacy and safety of etravirine at week 96 in treatmentexperienced HIV type-1-infected patients in the DUET-1 and DUET-2 trials. Antivir Ther 2010; 15:1045-1052.
5. Vingerhoets J, Tambuyzer L, Azijn H, Hoogstoel A, Nijs S, Peeters M, et al. Resistance profile of etravirine: combined analysis of baseline genotypic and phenotypic data from the randomized, controlled Phase III clinical studies. AIDS 2010; 24:503-514.
6. Gebo K, Martin S, Corbett C, De Smedt G. Impact of etravirine on hospitalizations and hospital-related costs: 48-week findings from pooled DUET trials [Poster]. Presented at: XVIIth International AIDS Conference. Mexico City, Mexico; 3-8 August 2008.
7. Cella D, Gilet H, Viala-Danten M, Peeters K, Dubois D, Martin S. Effects of etravirine versus placebo on health-related quality of life in treatment-experienced hiv patients as measured by the functional assessment of human immunodeficiency virus infection (FAHI) questionnaire in the DUET trials. HIV Clin Trials 2010; 11:18-27.
8. Mauskopf J, Brogan A, Martin S, Smets E. Cost effectiveness of darunavir/ritonavir in highly treatment-experienced, HIV-1-infected adults in the USA. Pharmacoeconomics 2010; 28 (Suppl 1):83-105.
9. Egger S, Petoumenos K, Kamarulzaman A, Hoy J, Sungkanuparph S, Chuah J, et al. Long-term patterns in CD4 response are determined by an interaction between baseline CD4 cell count, viral load, and time: the Asia Pacific HIV Observational Database (APHOD). J Acquir Immune Defic Syndr 2009; 50:513-520.
10. Tibotec, data on file. Analyses of pooled DUET 1 and DUET 2 clinical trial data. Mechelen, Belgium; 2008.
11. Simpson KN, Luo MP, Chumney E, Sun E, Brun S, Ashraf T. Costeffectiveness of lopinavir/ritonavir versus nelfinavir as the first-line highly active antiretroviral therapy regimen for HIV infection. HIV Clin Trials 2004; 5:294-304. (Pubitemid 39545402)
12. Olsen CH, Gatell J, Ledergerber B, Katlama C, Friis-Moller N, Weber J, et al. Risk of AIDS and death at given HIV-RNA and CD4 cell count, in relation to specific antiretroviral drugs in the regimen. AIDS 2005; 19:319-330. (Pubitemid 40396564)
13. Mocroft A, Ledergerber B, Katlama C, Kirk O, Reiss P, d'Arminio Monforte A, et al. Decline in the AIDS and death rates in the Euro SIDA study: an observational study. Lancet 2003; 362:22-29. (Pubitemid 36835816)
14. Krentz HB, Gill MJ. Cost of medical care for HIV-infected patients within a regional population from 1997 to 2006. HIV Med 2008; 9:721-730.
15. Cooper DA, Gatell J, Rockstroh J, Katlama C, Yeni P, Lazzarin A, et al. 48-week results from BENCHMRK-1, a phase III study of raltegravir (RAL) in patients failing antiretroviral therapy (ART) with triple-class resistant HIV-1 [Poster]. In: 15th Conference on Retroviruses and Opportunistic Infections. Boston, Massachusetts; 3-6 February 2008.
16. Steigbigel R, Kumar P, Eron J, Schechter M, Markowitz M, Loutfy M, et al. 48-week results from BENCHMRK-2, a phase III study of raltegravir (RAL) in patients failing antiretroviral therapy (ART) with triple-class resistant HIV-1 [Poster]. In: 15th Conference on Retroviruses and Opportunistic Infections. Boston, Massachusetts; 3-6 February 2008.
17. Steigbigel RT, Cooper DA, Kumar PN, Eron JE, Schechter M, Markowitz M, et al. Raltegravir with optimized background therapy for resistant HIV-1 infection. N Engl J Med 2008; 359:339-354.
18. Isentress (raltegravir) prescribing information. Whitehouse Station, NJ: Merck & Co., Inc.; May 2008 revision.
19. Hunt PW, Deeks SG, Rodriguez B, Valdez H, Shade SB, Abrams DI, et al. Continued CD4 cell count increases in HIV-infected adults experiencing 4 years of viral suppression on antiretroviral therapy. AIDS 2003; 17:1907-1915. (Pubitemid 37070276)
20. Cooper DA, Steigbigel RT, Gatell JM, Rockstroh JK, Katlama C, Yeni P, et al. Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection. N Engl J Med 2008; 359:355-365.
21. Ontario Ministry of Health and Long-Term Care. Ontario Drug Benefit Formulary, (2009). http://www.health.gov.on.ca/english/providers/program/drugs/ odbf-mn.html. [Accessed 9 November 2009].
22. Association Québécoise des Pharmaciens Propriétaires pharmacist list in Quebec, (2009). http://www.aqpp.qc.ca. [Accessed 29 January 2009].
23. Conseil du MédicamentQuébec (CdM). Capsules CdM, Fuzeon, (2008). http://www.cdm.gouv.qc.ca/site/116.963.0.0.1.0.phtml. [Accessed 22 March 2010].
24. Lewden C, Chene G, Morlat P, Raffi F, Dupon M, Dellamonica P, et al. HIV-infected adults with a CD4 cell count greater than 500 cells/mm3 on long-term combination antiretroviral therapy reach same mortality rates as the general population. J Acquir Immune Defic Syndr 2007; 46:72-77. (Pubitemid 47514615)
25. Statistics Canada. Deaths, 2006 (Catalog No. 84F0211X), (2009). http://www.statcan.gc.ca/pub/84f0211x/84f0211x2006000-eng.htm. [Accessed 26 June 2009].
26. Krentz HB, Kliewer G, Gill MJ. Changing mortality rates and causes of death for HIV-infected individuals living in Southern Alberta, Canada from 1984 to 2003. HIV Med 2005; 6:99-106. (Pubitemid 40425973)
27. Yip B, Linia VD, Burke TA, Druyts EF, Hogg RS. Nondrug healthcare resource utilization and costs of managing HIV/AIDS patients prescribed antiretroviral therapy: evidence from a contemporary HIV practice in Canada [Poster]. In: 11th European AIDS Conference. Madrid, Spain; 24-27 October 2007.
28. London Health Science Center, Canada (LHSC). Specific analysis for cost data, fiscal 2006-2007. Case costing. London Health Science Center, Canada; 20 February 2008.
29. Clotet B, Bellos N, Molina JM, Cooper D, Goffard JC, Lazzarin A, et al. Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: a pooled subgroup analysis of data from two randomised trials. Lancet 2007; 369:1169-1178. (Pubitemid 46541620)
30. Tibotec, data on file. Analyses of pooled POWER 1 and POWER 2 clinical trial data. Mechelen, Belgium; 2006.
31. Selzentry (maraviroc) prescribing information. New York, NY: Pfizer, Inc.; 2007 revision.
32. Gulick RM, Lalezari J, Goodrich J, Clumeck N, DeJesus E, Horban A, et al. Maraviroc for previously treated patients with R5 HIV-1 infection. N Engl J Med 2008; 359:1429-1441.
33. Van der Ryst E, Cooper D, Konourina I, Saag M, Goodrich J, Tawadrous M, et al. Efficacy of maraviroc in combination with at least one other potent new antiretroviral drug: 24-week combined analysis of the MOTIVATE 1 and 2 studies [Poster]. In: 4th International AIDS Society Conference on HIV Pathogenesis, Treatment, and Prevention. Sydney, Australia; 22-25 July 2007.
34. Braithwaite RS, Meltzer DO, King JT Jr, Leslie D, Roberts MS. What does the value of modern medicine say about the 50 000 per quality-adjusted life-year decision rule?. Med Care 2008; 46:349-356.
35. Laupacis A, Feeny D, Detsky AS, Tugwell PX. How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations. CMAJ 1992; 146:473-481.
36. Kuhne FC, Chancellor J, Mollon P, Myers DE, Louie M, Powderly WG. A microsimulation of the cost-effectiveness of maraviroc for antiretroviral treatment-experienced HIVinfected individuals. HIV Clin Trials 2010; 11:80-99.
37. Sax PE, Losina E, Weinstein MC, Paltiel AD, Goldie SJ, Muccio TM, et al. Cost-effectiveness of enfuvirtide in treatmentexperienced patients with advanced HIV disease. J Acquir Immune Defic Syndr 2005; 39:69-77. (Pubitemid 40617021)
38. Elbasha EE, Szucs T, Chaudhary MA, Kumar RN, Roediger A, Cook JR, et al. Cost-effectiveness of raltegravir in antiretroviral treatment-experienced HIV-1-infected patients in Switzerland. HIV Clin Trials 2009; 10:233-253.
39. Chaudhary MA, Moreno S, Kumar RN, Nocea G, Elbasha E. Cost-effectiveness analysis of raltegravir in treatmentexperienced HIV type 1-infected patients in Spain. AIDS Res Hum Retroviruses 2009; 25:679-689.
40. Fatkenheuer G, Nelson M, Lazzarin A, Konourina I, Hoepelman AI, Lampiris H, et al. Subgroup analyses of maraviroc in previously treated R5 HIV-1 infection. N Engl J Med 2008; 359:1442-1455.